Carvedilol's actions are largely mediated by endogenous nitric oxide

Revista Portuguesa de Cardiologia

Volumn 25, Issue 10, 2006, Pages 911-917

  Afonso, Ricardo A ^a   Patarrão, Rita S ^b   Macedo, Maria Paula ^b   Carmo, M Mota ^b  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b NONE

Author keywords

Arterial blood pressure; Carvedilol; Heart failure; Hypertension; Nitric oxide (NO)

Indexed keywords

CARVEDILOL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PENTOBARBITAL; RO 2052170;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HEART FAILURE; HEART HEMODYNAMICS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROPANOLAMINES; RATS; RATS, WISTAR; TIME FACTORS;

EID: 33845205588     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004;93:3B-6B.
2. Ruffolo RR, Jr., Boyle DA, Venuti RP, Lukas MA. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens 1993;7 Suppl 1:S2-15.
3. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-52.
4. Kawada T, Ishibashi T, Nakazawa M, Satoh S, Imai S. Adrenoceptor-blocking activity and cardiohemodynamic effects of carvedilol in animals. J Cardiovasc Pharmacol 1990;16:147-53.
5. Prichard BN, Tomlinson B. Progress in antihypertensive therapy with a multiple-action drug. Drugs 36 Suppl 1988;6:20-5.
6. Messerli FH, Grossman E. [beta]-blockers in hypertension: is carvedilol different? The American Journal of Cardiology 2004;93:7-12.
7. Lopez BL, Christopher TA, Yue TL, Ruffolo R, Feuerstein GZ, Ma XL. Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995;51:165-73.
8. Saijonmaa O, Metsarinne K, Fyhrquist F. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press 1997;6:24-8,.
9. Kurosaki K, Ikeda U, Maeda Y, Shimada K. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J Mol Cell Cardiol 2000;32:333-9.
10. Vanhoutte PM. Say NO to ET. J Auton Nerv Syst 2000;81:271-7.
11. Hu N, Chiamvimonvat T, Yamagishi E, Marban H. Direct Inhibition of Expressed Cardiac L-Type Ca2+ Channels by S-Nitrosothiol Nitric Oxide Donors. Circ Res 1997;81:742-52.
12. Moncada S. Nitric oxide. J Hypertens Suppl 1994;12:S35-9.
13. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995;41:892-6.
14. Wennmalm A, Benthin G, Petersson AS. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br J Pharmacol 1992;106:507-8.
15. Yang F, Troncy E, Francoeur M, Vinet B, Vinay P, Czaika G, Blaise G. Effects of reducing reagents and temperature on conversion of nitrite and nitrate to nitric oxide and detection of NO by chemiluminescence. Clin Chem 1997;43:657-62.
16. Cox RD, Frank CW. Determination of nitrate and nitrite in blood and urine by chemiluminescence. J Anal Toxicol 1982;6:148-52.
17. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989;61:2715-8.
18. Nichols AJ, Gellai M, Ruffolo RR, Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 1991;5:25-38.
19. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Louden C, Arleth A, Poste G, Ruffolo RR, Jr., Feuerstein GZ. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993;90:6189-93.
20. Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000;45:788-94.
21. Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, Murray GD, Coats AJ, Cleland JG, Pennell DJ. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart 2004;90:760-4.
22. Villarroya M, Herrero CJ, Ruiz-Nuno A, de Pascual R, del Valle M, Michelena P, Grau M, Carrasco E, Lopez MG, Garcia AG. PF9404C, a new slow NO donor with beta receptor blocking properties. Br J Pharmacol 1999;128:1713-22.
23. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2003;63:1697-741.
24. Macedo MP, Lautt WW. Shear-induced modulation by nitric oxide of sympathetic nerves in the superior mesenteric artery. Can J Physiol Pharmacol 1996;74:692-700.
25. Macedo MP, Lautt WW. Shear-induced modulation of vasoconstriction in the hepatic artery and portal vein by nitric oxide. Am J Physiol 1998;274:G253-60.
26. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 2004;61:402-13.
27. Ritchie RH, Rosenkranz AC, Huynh LP, Stephenson T, Kaye DM, Dusting GJ. Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling. Am J Physiol Heart Circ Physiol 2004;287:H1179-85.